Form 8-K - Current report:
SEC Accession No. 0001564590-21-039201
Filing Date
2021-07-29
Accepted
2021-07-29 16:54:59
Documents
14
Period of Report
2021-07-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cycn-8k_20210729.htm   iXBRL 8-K 39583
2 EX-99.1 cycn-ex991_6.htm EX-99.1 47463
3 GRAPHIC gakm5ae2v0fj000001.jpg GRAPHIC 65626
  Complete submission text file 0001564590-21-039201.txt   320074

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cycn-20210729.xsd EX-101.SCH 5780
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cycn-20210729_lab.xml EX-101.LAB 20227
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cycn-20210729_pre.xml EX-101.PRE 12087
7 EXTRACTED XBRL INSTANCE DOCUMENT cycn-8k_20210729_htm.xml XML 3680
Mailing Address 301 BINNEY STREET CAMBRIDGE MA 02142
Business Address 301 BINNEY STREET CAMBRIDGE MA 02142 617-621-7722
Cyclerion Therapeutics, Inc. (Filer) CIK: 0001755237 (see all company filings)

EIN.: 831895370 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38787 | Film No.: 211128286
SIC: 2834 Pharmaceutical Preparations